Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2)

نویسندگان

  • Tadeusz Robak
  • Jerzy Z. Blonski
  • Joanna Gora-Tybor
  • Krzysztof Jamroziak
  • Jadwiga Dwilewicz-Trojaczek
  • Agnieszka Tomaszewska
  • Lech Konopka
  • Bernadetta Ceglarek
  • Anna Dmoszynska
  • Malgorzata Kowal
  • Janusz Kloczko
  • Beata Stella-Holowiecka
  • Kazimierz Sulek
  • Malgorzata Calbecka
  • Krystyna Zawilska
  • Kazimierz Kuliczkowski
  • Aleksander B. Skotnicki
  • Krzysztof Warzocha
  • Marek Kasznicki
چکیده

Tadeusz Robak, Jerzy Z. Blonski, Joanna Gora-Tybor, Krzysztof Jamroziak, Jadwiga Dwilewicz-Trojaczek, Agnieszka Tomaszewska, Lech Konopka, Bernadetta Ceglarek, Anna Dmoszynska, Malgorzata Kowal, Janusz Kloczko, Beata Stella-Holowiecka, Kazimierz Sulek, Malgorzata Calbecka, Krystyna Zawilska, Kazimierz Kuliczkowski, Aleksander B. Skotnicki, Krzysztof Warzocha, Marek Kasznicki and the Polish Leukemia Group (PALG CLL2)

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

CLINICAL TRIALS AND OBSERVATIONS Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2)

Tadeusz Robak, Jerzy Z. Blonski, Joanna Gora-Tybor, Krzysztof Jamroziak, Jadwiga Dwilewicz-Trojaczek, Agnieszka Tomaszewska, Lech Konopka, Bernadetta Ceglarek, Anna Dmoszynska, Malgorzata Kowal, Janusz Kloczko, Beata Stella-Holowiecka, Kazimierz Sulek, Malgorzata Calbecka, Krystyna Zawilska, Kazimierz Kuliczkowski, Aleksander B. Skotnicki, Krzysztof Warzocha, Marek Kasznicki, and the Polish Leu...

متن کامل

The multicenter trial SAKK 37/95 of cladribine, cyclophosphamide and prednisone in the treatment of chronic lymphocytic leukemias and low-grade non-Hodgkin's lymphomas.

A multicenter trial was performed to confirm the therapeutic efficacy and the toxicity profile of the combination of cladribine, cyclophosphamide and prednisone in low-grade non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Twenty-three adults with previously treated (61%) or untreated (39%) NHL International Working Formulation A or Binet B and C CLL were administered cladri...

متن کامل

Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia.

BACKGROUND One of the mechanisms of action of cladribine is the inhibition of DNA repair of damage caused by radiation, alkylating agents, or other drugs. To determine its antitumor activity in combination with cyclophosphamide, we initiated a Phase II trial of the two agents in patients with advanced chronic lymphocytic leukemia (CLL) or prolymphocytic leukemia (PLL). METHODS Twenty-nine pat...

متن کامل

Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies.

The aim of our study was to determine the effectiveness and toxicity of combined chemotherapy consisting of cladribine (2-chloro-deoxyadenosine, 2-CdA), mitoxantrone and cyclophosphamide (CMC regimen) in the treatment of refractory or relapsed indolent lymphoproliferative disorders. The treatment course consisted of 2-CdA given at a dose of 0.12 mg/kg/24 h in a 2-h intravenous infusion for 5 (C...

متن کامل

Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial.

Cladribine (2-chlorodeoxyadenosine, 2-CdA) treatment-associated infections may shorten potentially long-term survival in hairy cell leukemia (HCL). In search of the optimal mode of 2-CdA administration, 132 patients with untreated HCL were randomized to receive either standard 5-day 2-CdA protocol or a novel schedule of 6 weekly 2-CdA infusions suggested to be less toxic. Analysis of treatment ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2006